Chengdu Huasheng Biologicals (stock code: 300122.SZ): Application for clinical trial of recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cell) accepted.

China Fortune Financial News APP News, Chongqing Fuchuang (300122.SZ) announced that the recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cells) developed by its wholly-owned subsidiary Anhui Fuchuang Long Scientists Biopharmaceutical Co., Ltd. (referred to as "Fuchuang Long Scientists") has obtained a notice of acceptance of drug clinical trial application from the National Medical Products Administration. Within 60 days from the date of acceptance, if no denial or questioning opinions are received from the Drug Evaluation Center, Fuchuang Long Scientists can carry out clinical trials according to the submitted plan.